Abstract:Neurofibrillary tangles (NFT), scaffolds of highly phosphorylated tau protein, are a core pathological feature of Alzheimer's disease (AD) and several other neurodegenerative diseases collectively termed tauopathies, which include progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and certain frontotemporal dementias. There are six isoforms of human tau in brain and over 40 serine (S), threonine (T), and tyrosine (Y) tau phosphorylation sites have been identified. Progressive site-specific phosphorylation of tau at specific S/T/Y sites is hypothesized to cause both functional deficits as well as gain-of-function toxicity that ultimately lead to NFT formation, synaptic loss, and cognitive dysfunction. Despite being clinically distinct diseases it remains unclear whether site-specific tau phosphorylation differs between AD and other tauopathies. Following tissue homogenization and in-solution trypsin digestion, phosphopeptides were enriched by an optimized immobilized metal affinity chromatography (IMAC) protocol using ferric chloride from individual AD, tauopathy (CBD and PSP) and age-matched control postmortem human brain tissues (n= 7 per group). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was subsequently employed to identify and quantify tau phosphopeptides among other globally enriched phosphopeptides from each tissue sample. Accurate peptide mass and retention time was used to derive signal intensity for every phosphopeptide across LC-MS/MS runs for each case. In total, 77 tau phosphopeptides representing 32 S/T/Y sites were analyzed by WeiGhted Correlation Network Analysis (WGCNA) to delineate tau phosphosites co-enriched in a disease specific manner. Correlated intensity with other phosphopeptides from the same samples, and the phosphorylation pattern of tau itself each suggest that mechanisms underlying site-specific tau phosphorylation differ between AD and other tauopathies. This study highlights the utility of mass spectrometry based proteomics to quantify tau and other brain phosphosignatures with potential to discriminate AD from other tauopathies.

Novel Peptidomic Approach for Identification of Low and High Molecular Weight Tauopathy Peptides Following Calpain Digestion, and Primary Culture Neurotoxic Challenges

Novel Cathepsin D Inhibitors Block the Formation of Hyperphosphorylated Tau Fragments in Hippocampus

Neurobiochemical, Peptidomic, and Bioinformatic Approaches to Characterize Tauopathy Peptidome Biomarker Candidates in Experimental Mouse Model of Traumatic Brain Injury

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

O4‐12‐03: Brain Phosphoproteome Network Analysis Discriminates Alzheimer's Disease from Other Tauopathies

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression

Novel Cell Model for Tauopathy Induced by a Cell-Permeable Tau-Related Peptide

Screening of Tau Protein Kinase Inhibitors in a Tauopathy-Relevant Cell-Based Model of Tau Hyperphosphorylation and Oligomerization

Synthesis and conformational properties of phosphopeptides related to the human tau protein.

High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy

Quantitative profiling of posttranslational modifications of pathological tau via sarkosyl fractionation and mass spectrometry

Mass spectrometry identifies tau C-terminal phosphorylation cluster during neuronal hyperexcitation

Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers

Single‐Molecule Characterization and Super‐Resolution Imaging of Alzheimer's Disease‐Relevant Tau Aggregates in Human Samples

Probing tau citrullination in Alzheimer's disease brains and mouse models of tauopathy

Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer's disease

Sensitive detection and propagation of brain-derived tau assemblies in HEK293 based wild-type tau seeding assays

Conformation‐specific anti‐tau antibodies distinguish human tauopathies

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

Separation of Isomeric Tau Phosphopeptides from Alzheimer’s Disease Brain by Cyclic Ion Mobility Mass Spectrometry